Answers are grounded in this paper and cite their sources.
Gentamicin has been in clinical use for over 60 years, and to this day it remains a challenge to replace. It is bactericidal in a concentration dependent fashion, effective against aerobic Gram-negative pathogens and cost effective, making it a good first line of choice in resource limited countries where newer agents are not available. The primary limitations are nephrotoxicity, ototoxicity, and resistance—with biofilm tolerance representing the most difficult of these. The survival of bacteria growing in a sessile state behind a matrix of polysaccharides, proteins, and extracellular DNA can be orders of magnitude greater than that of their planktonic counterparts: not only is diffusion of the drug slowed, but metabolically dormant persister cells cannot import a drug that requires an active membrane potential to enter. Increasing the dose cannot overcome this barrier; an entirely new delivery approach is required. This review is organized around three themes—fabrication, performance, and translation—covering the present generation of gentamicin nanoformulations. Studies were drawn from a curated database of primary literature, with quantitative comparison restricted to reports providing verified encapsulation data. The encapsulation efficiency (EE %) and drug loading (DL %) reported in studies with verified data are compared across 13 carrier types (Table 1): polymeric (chitosan, polydopamine, PLGA, Eudragit RS-100, and alginate nanoparticles), lipid-based (liposomes, niosomes, bilosomes, and solid lipid and liquid crystal nanoparticles), polymer-lipid hybrid, and inorganic (cerium-doped bioactive glass and CaCO₃) carriers, while mesoporous silica and molecularly imprinted systems are discussed qualitatively. Reported EE values span nearly 90 %age points, from about 6 % for liposomes to 95.3 % for an optimized solid lipid system, illustrating how strongly encapsulation performance depends on carrier chemistry rather than on the drug itself. The incompatibility of the physicochemical nature of a polycationic hydrophilic drug and hydrophobic carrier matrices is a real incompatibility that has driven researchers to develop the three following strategies: hydrophobic ion-pairing, pH-gated mesoporous architectures, and in situ polymerization strategies. Gentamicin delivery systems are also discussed that respond to stimuli in the infection site such as those that release the antibiotic upon acidification, bacterial enzyme activity, or the application of an external magnetic field; and multi-modal delivery systems are reviewed that combine the antibiotic with thymoquinone, curcumin, silver nanoparticles, or surface-adsorbed DNase I, which act to combat the biofilm matrix rather than just to penetrate it. The review concludes that the translational gap remains large: in vivo testing remains limited, manufacturing protocols are not readily scalable, and direct in vivo demonstration of reduced nephrotoxicity (the principal purpose of encapsulation) remains sparse, confined largely to a handful of nephroprotective co-formulation studies.
No takes yet. Share an insight, caveat, or question.
Maleki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: